Junshi Biosciences Shareholders Approve H-Share Buyback MandateTip Ranks·2 days ago, 06:09 AM01877+0.32%688180+0.90%
Junshi Biosciences Completes RMB300 Million Technology Innovation Bond IssuanceTip Ranks·Jul 22 at 08:08 AM01877+0.32%688180+0.90%
Junshi Biosciences Announces Acceptance of the Supplemental Application for Toripalimab plus Chemotherapy as Perioperative Treatment for Resectable Stage Ⅱ-Ⅲ NSCLCUnusual Whales·Jul 21 at 06:12 PM01877+0.32%688180+0.90%
Junshi Biosciences Wins NMPA Nod to Expand Toripalimab Use in Early-Stage Lung CancerTip Ranks·Jul 21 at 09:09 AM01877+0.32%688180+0.90%
Shanghai Junshi says China regulator accepts label expansion filing for toripalimab chemo in resectable stage II-III NSCLCPUBT·Jul 21 at 08:23 AM01877+0.32%688180+0.90%
Junshi Biosciences Calls EGM to Seek Mandate for H-Share BuybackTip Ranks·Jul 8 at 09:38 AM688180+0.90%01877+0.32%
JUNSHI BIO Opens 11.11% Higher After Signing Licensing Agreement with Fosun WanbangAASTOCKS News·Jul 1 at 08:50 PM01877+0.32%688180+0.90%
Junshi Biosciences Enters Licensing Collaboration with Fosun Wanbang on Roconkibart (IL-17A)GlobeNewswire·Jul 1 at 07:43 PM688180+0.90%01877+0.32%
Junshi Biosciences licenses JS005 rights in Greater China to Fosun Wanbang for CNY 215 million upfrontPUBT·Jul 1 at 06:28 AM688180+0.90%01877+0.32%
Junshi Biosciences says contributed JV assets valued at RMB 53.08 million in supplemental announcementPUBT·Jun 26 at 09:51 AM688180+0.90%01877+0.32%
Shanghai Junshi Biosciences names Chen Liang as independent non-executive directorPUBT·Jun 26 at 08:04 AM01877+0.32%688180+0.90%
Shanghai Junshi Biosciences files directors list with Hong Kong exchangePUBT·Jun 26 at 07:56 AM01877+0.32%688180+0.90%
